跳至主要内容
CAS 1 条记录

CAS 113-45-1

CAS 113-45-1 与法规 1223/2009 附件 II–VI 中的 1 条欧盟附件记录相匹配。

CAS 113-45-1 的记录

1 共

化学身份与性质

CAS 113-45-1 的 PubChem 二维化学结构
CAS 113-45-1PubChem CID 4158

Methylphenidate

Methyl phenyl(piperidin-2-yl)acetate is a amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group. It is a methyl ester, a member of piperidines and a beta-amino acid ester. — ChEBI

IUPAC 名称
methyl 2-phenyl-2-piperidin-2-ylacetate
分子式
C14H19NO2
分子量
233.31 g/mol
精确质量
233.141578849 Da
XLogP3
0.2
拓扑极性表面积
38.3 Ų
氢键供体
1
氢键受体
3
共价单元
1
已定义的立体中心
0

又称

MethylphenidanPhenidylateCalocainPlimasineMethyl phenidylacetateMetilfenidatoMethylphenidatumMethyl phenidate
另有 16 个已报告名称
4311/B CibaDaytranaalpha-Phenyl-2-piperidineacetic acid methyl esterMethyl alpha-phenyl-alpha-(2-piperidyl)acetateNCI-C56280Methyl 2-phenyl-2-(piperidin-2-yl)acetate2-Piperidineacetic acid, alpha-phenyl-, methyl esterCotempla XR-ODTMethyl alpha-phenyl-alpha-2-piperidinylacetatealpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl esterMetilfenidat hydrochlorideThreo-dl-methylphenidatePrc-063Methylphenidate extended releaseRitalineRefChem:6033
外部数据库标识符

来自其他科学数据库的证据

NIH PubChem PUG-View
标识符精确匹配4158

Attributed physical-property, hazard, environmental and use annotations.

  • Exposure Routes: Oral. Readily absorbed in a biphasic manner when orally administered (tablets) to children diagnosed with ADHD and to healthy adults. In children and adults males, after administration of a single oral dose of Ritalin LA and Ritalin given in two doses 4 hours apart, peak plasma concentration is reached approximately 2 hours for the first phase and 5-6 hours for the second phase. The absolute oral bioavailability of methylphenidate in children was 22±8% for d-methylphenidate and 5±3% for l-methylphenidate. These low values suggest that methylphenidate is highly metabolized presystemically. 来源: Toxin and Toxin Target Database (T3DB)
  • Signal: Warning 来源: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]; H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H341 (100%): Suspected of causing genetic defects [Warning Germ cell mutagenicity] 来源: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P203, P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P318, P321, P330, P332+P317, P337+P317, P362+P364, P405, and P501 (click each P-code to see the statement) 来源: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. 来源: European Chemicals Agency (ECHA)
  • Signal: Danger 来源: Hazardous Substances Data Bank (HSDB)
  • GHS Hazard Statements: H302: Harmful if swallowed [Warning Acute toxicity, oral]; H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] 来源: Hazardous Substances Data Bank (HSDB)
  • Precautionary Statement Codes: P233, P260, P264, P270, P271, P284, P301+P317, P304+P340, P330, P342+P316, P403, and P501 (click each P-code to see the statement) 来源: Hazardous Substances Data Bank (HSDB)
  • Health Effects: Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion. 来源: Toxin and Toxin Target Database (T3DB)
  • Toxicity Summary: IDENTIFICATION AND USE: Methylphenidate Hydrochloride is a psychostimulant used to treat different behavioral disorders. Indications: Used to treat narcolepsy and hyperkinetic states in children (as an adjunct to psychological, educational and social measures) for amphetamine, dextroamphetamine and ethylphenidate. It is misused for performance enhancement and relief of fatigue. Abuse either orally or by injection is extremely common. HUMAN EXPOSURE AND TOXICITY: Main risks include: Acute central nervous system (CNS) stimulation, cardiotoxicity causing tachycardia, arrhythmias, hypertension and cardiovascular collapse. High risk of dependency and abuse. Cardiovascular effects include: palpitation, chest pain, tachycardia, arrhythmias and hypertension; cardiovascular collapse can occur in severe poisoning. Myocardial ischemia, infarction and ventricular dysfunction are described. CNS effects include: stimulation of CNS, tremor, restlessness, agitation, insomnia, increased motor activity, headache, convulsions, coma and hyperreflexia. Stroke and cerebral vasculitis have been observed. Gastrointestinal effects include: vomiting, diarrhea and cramps. Genitourinary effects include: incre 来源: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: The first step in a medication overdose is to immediately contact a poison control center for the appropriate management steps. Doses that exceed 60 mg of the immediate-release formulation or 120 mg of the extended-release formulation can be considered toxic. If the overdosed quantity is unknown, the patient should be assessed for signs and symptoms such as tremors, hyperreflexia, convulsions, euphoria, confusion, hallucinations, delirium, flushing, and fever, in addition to the common adverse effects mentioned above. Supportive care with supplemental oxygen, intravenous fluids, and external cooling methods is the mainstay of treatment. Multiple studies have shown that benzodiazepines are an option, especially if dystonia, agitation, or convulsions are present. 来源: StatPearls
  • Toxicity Summary: Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Alteration of serotonergic pathways via changes in dopamine transport may result. 来源: Toxin and Toxin Target Database (T3DB)
  • Environmental Bioconcentration: An estimated BCF of 3 was calculated in fish for methylphenidate(SRC), using a log Kow of 0.20(1) and a regression-derived equation(2). According to a classification scheme(2), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC). 来源: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 1600(SRC), determined from a structure estimation method(2), indicates that methylphenidate is expected to have low mobility in soil(SRC). The pKa of methylphenidate is 8.9(3), indicating that this compound will exist partially in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization of the neutral species of methylphenidate from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 4.4X10-9 atm-cu m/mole(SRC), using a fragment constant estimation method(5). Methylphenidate is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 5.9X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2015). 来源: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 1600(SRC), determined from a structure estimation method(2), indicates that methylphenidate is expected to adsorb to suspended solids and sediment(SRC). Volatilization of the neutral species from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 4.4X10-9 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). A pKa of 8.9(5) indicates methylphenidate will exist partially in the cation form at pH values of 5 to 9 and, therefore, volatilization from water surfaces is not expected to be an important fate process(SRC). According to a classification scheme(6), an estimated BCF of 3(SRC), from its log Kow of 0.20(7) and a regression-derived equation(2), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Base-catalyzed second-order hydrolysis rate constant half-lives of 23 and 2.3 years at pH values of 7 and 8, respectively(2), suggest that hydrolysis may be a slow environmental fate process. Biodegradation data in water were not available(SRC, 2015). 来源: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), methylphenidate, which has an estimated vapor pressure of 5.9X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase methylphenidate is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 1 hr(SRC), calculated from its rate constant of 1.1X10-10 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Particulate-phase methylphenidate may be removed from the air by wet and dry deposition(SRC). Methylphenidate contains chromophores that absorb at wavelengths >290 nm(4) and, therefore, may be susceptible to direct photolysis by sunlight(SRC). 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: Methylphenidate (DEA Code Number: 1724) is a Schedule II controlled substance. 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: Schedule II Controlled Substance: (A) The drug or other substance has a high potential for abuse; (B) The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions; and (C) Abuse of the drug or other substances may lead to severe psychological or physical dependence. 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION (VET) 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: Central Nervous System Stimulants; Dopamine Uptake Inhibitors 来源: Hazardous Substances Data Bank (HSDB)
  • Uses: Use (kg) in Switzerland (2009): >250; Use (kg; approx.) in Germany (2009): >1000; Use (kg) in USA (2002): 9090; Consumption (g per capita) in Switzerland (2009): 0.032; Consumption (g per capita; approx.) in Germany (2009): 0.012; Consumption (g per capita) in the USA (2002): 0.032; Excretion rate: 0.1; Calculated removal (%): 92.1 来源: NORMAN Suspect List Exchange
  • Uses: For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. 来源: Toxin and Toxin Target Database (T3DB)

映射方: Existing checksum-valid CAS to unique PubChem CID match. 检索时间: 2026-08-31. 打开来源记录

科学分类和危害注释仅提供背景信息,不能取代上方所示针对具体市场的监管决定。

其他来源的覆盖范围和匹配状态
来源结果已检查
NIH PubChem PUG-View精确匹配2026-08-31

已记录的无匹配结果是该来源已被检查的有效证据;这并不表示该物质在别处不存在。

于 2026-09-02 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

本站如何使用 CAS 113-45-1

CAS 113-45-1 是化学文摘社 (Chemical Abstracts Service) 的标识符,用于将本页对应到特定物质。在当前数据集中,有 1 条欧盟附件记录共用该标识符,可帮助您交叉核对同一物质是出现在一种还是多种监管情境中。

当供应商规格书、SDS 或原料档案给出 CAS 113-45-1,而您需要在一处查看所有关联的附件 II–VI 记录时,请使用本页。上方的条目卡片是查看浓度限值、警示语、附件归属和产品类型条件的最快途径。

常见问题

以 CAS 113-45-1 标识的物质,如果在不同情境下适用不同条件,可能出现在欧盟化妆品法规的多个附件中。例如,某物质可能在附件 III 中按特定条件受到限制,同一 CAS 也可能在附件 IV 中作为准用着色剂按另行规定的条件出现。每个条目都必须单独审查。

将 CAS 编号与您的原料规格书和 CoA 文件进行交叉核对。当该 CAS 出现在附件 II 时,应核实其不存在。当其出现在附件 III 时,应核实您的配方满足浓度限值和产品类型条件。共用此 CAS 编号的所有附件条目均列于上方。

CAS 编号由美国化学文摘社 (Chemical Abstracts Service) 分配,全球通用。EC 编号是来自 EINECS、ELINCS 或 NLP 清单等名录的欧盟委员会标识符。两种标识符都可能出现在欧盟化妆品附件条目中。有些物质两者都有,有些只有其一,一些较旧的条目可能两者都没有。

INCI 检查器接受成分名称、CAS 编号和 EC 编号。可直接检查此 CAS 编号,然后对照供应商规格书和所有关联的附件条件核实结果。

工具与后续步骤

检查您的配方

扫描完整的 INCI 成分表,然后使用 CAS 113-45-1 交叉核对匹配物质背后的任何供应商文件。

INCI 检查器

浏览附件

按类别浏览所有欧盟化妆品法规附件。

全部附件

按名称搜索

搜索您的文件中与 CAS 113-45-1 并列出现的 INCI 名称、别名或相关标识符。

搜索